Principal Financial Group Inc Replimune Group, Inc. Transaction History

Principal Financial Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	SELL	$6.87 - $9.31 $10,792 - $14,626	-1,571 Reduced 10.69%	13,129 $107,000
Q4 2023 Feb 07, 2024	SELL	$6.75 - $16.18 $324 - $776	-48 Reduced 0.33%	14,700 $123,000
Q3 2023 Nov 02, 2023	BUY	$15.96 - $22.18 $34,553 - $48,019	2,165 Added 17.21%	14,748 $252,000
Q2 2023 Aug 07, 2023	SELL	$15.65 - $24.1 $923 - $1,421	-59 Reduced 0.47%	12,583 $292,000
Q1 2023 May 09, 2023	BUY	$17.48 - $29.09 $38,648 - $64,317	2,211 Added 21.2%	12,642 $223,000
Q4 2022 Feb 09, 2023	BUY	$17.09 - $27.91 $178,265 - $291,129	10,431 New	10,431 $283,000
Q4 2021 Feb 09, 2022	SELL	$25.43 - $34.25 $234,769 - $316,196	-9,232 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$28.98 - $39.54 $43,441 - $59,270	-1,499 Reduced 13.97%	9,232 $274,000
Q2 2021 Aug 10, 2021	BUY	$28.5 - $39.37 $305,833 - $422,479	10,731 New	10,731 $412,000
Q1 2021 May 10, 2021	SELL	$30.22 - $45.57 $182,075 - $274,559	-6,025 Closed	0 $0
Q4 2020 Feb 08, 2021	BUY	$23.5 - $52.65 $141,587 - $317,216	6,025 New	6,025 $230,000

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $693M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.